Zobrazeno 1 - 10
of 29
pro vyhledávání: '"D. R. D'Adamo"'
Autor:
Peter A. Kaufman, Ella Kleynerman, Claudio Savulsky, Virginia G. Kaklamani, Sharon Wilks, Michaela L. Tsai, Grace Wang, Yuan Yuan, Dongyuan Xing, D. R. D'Adamo, Gursel Aktan, Eleni Andreopoulou, Debra A. Patt, Ruth O'Regan, Sara M. Tolaney, Sami Diab, Kevin Kalinsky, Vassiliki Karantza
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(11)
Purpose: As monotherapies, eribulin (chemotherapy) and pembrolizumab (immunotherapy) have shown promise for patients with metastatic triple-negative breast cancer (mTNBC). This phase Ib/II study examined eribulin plus pembrolizumab as a potential mTN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18ff08c7305436447d9f5e35e7471a1
https://pubmed.ncbi.nlm.nih.gov/33727258
https://pubmed.ncbi.nlm.nih.gov/33727258
Autor:
D. R. D'Adamo, Giovanni Grignani, George D. Demetri, Brian A. Van Tine, Robert G. Maki, Patrick Schöffski, Robin L. Jones, Sant P. Chawla, Thierry Alcindor, Matthew Guo, Jean-Yves Blay
Publikováno v:
Journal of Clinical Oncology. 35:3433-3439
Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overall survival (OS) for the eribulin arm, with a manageable toxicity profile. We now rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d7d40b11e3e6797cbda0f18084252ab
https://doi.org/10.1200/jco.2016.71.6605
https://doi.org/10.1200/jco.2016.71.6605
Autor:
Yan Jia, Sebastian Bauer, D. R. D'Adamo, Jean-Yves Blay, Robert G. Maki, Anders Krarup-Hansen, Patrick Schöffski, Charlotte Benson
Publikováno v:
British Journal of Cancer
Blay, J Y, Schöffski, P, Bauer, S, Krarup-Hansen, A, Benson, C, D’Adamo, D R, Jia, Y & Maki, R G 2019, ' Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, open-label, randomised study ', British Journal of Cancer, vol. 120, no. 11, pp. 1026-1032 . https://doi.org/10.1038/s41416-019-0462-1
Blay, J Y, Schöffski, P, Bauer, S, Krarup-Hansen, A, Benson, C, D’Adamo, D R, Jia, Y & Maki, R G 2019, ' Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, open-label, randomised study ', British Journal of Cancer, vol. 120, no. 11, pp. 1026-1032 . https://doi.org/10.1038/s41416-019-0462-1
BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. METHODS: Patients ≥18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS ≤2, and ≥2 prior treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3b983b26448ddfa2191674e474512fc
https://www.ncbi.nlm.nih.gov/pubmed/31065111
https://www.ncbi.nlm.nih.gov/pubmed/31065111
Autor:
Vassiliki Karantza, Sharon Wilks, Michaela L. Tsai, Dongyuan Xing, Grace Wang, Debra A. Patt, Yuan Yuan, D. R. D'Adamo, Sara M. Tolaney, Kevin Kalinsky, Peter A. Kaufman, Gursel Aktan, Virginia G. Kaklamani, Sami Diab, Ella Kleynerman, Eleni Andreopoulou, Ruth O'Regan
Publikováno v:
Journal of Clinical Oncology. 38:1015-1015
1015 Background: As monotherapies, both ERI (a chemotherapeutic microtubule inhibitor) and PEMBRO (a programmed death [PD]-1 blocking immunotherapy) have shown promising antitumor activity in mTNBC. Emerging data suggest that the addition of immunoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30620c50e8a579525a17259a386d4ded
https://doi.org/10.1200/jco.2020.38.15_suppl.1015
https://doi.org/10.1200/jco.2020.38.15_suppl.1015
Autor:
Ana Sastre Urgelles, Rachael Scott, Christof M. Kramm, Franco Locatelli, Yan Jia, Udo Kontny, Francisco Bautista, D. R. D'Adamo, Michela Casanova, Claudio Favre, Jagadeesh Aluri, Raquel Hladun Alvaro, Dirk Reinhardt
Publikováno v:
Journal of Clinical Oncology. 38:10535-10535
10535 Background: ERI is an inhibitor of microtubule dynamics. IRI is used to treat pediatric sarcomas. In the pediatric preclinical testing program, ERI was well tolerated and had promising activity compared with vincristine (a common chemotherapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::201c34c06f4f37219c89cffe16e24026
https://doi.org/10.1200/jco.2020.38.15_suppl.10535
https://doi.org/10.1200/jco.2020.38.15_suppl.10535
Autor:
Richard D. Carvajal, Robert A. Lefkowitz, Li-Xuan Qin, Mary Louise Keohan, Robert G. Maki, D. R. D'Adamo, Mark A. Dickson, William D. Tap, Marietta O. Ezeoke, Catherine M. Hirst, Martee L. Hensley, Gary K. Schwartz, Linda Ahn, Cristina R. Antonescu
BACKGROUND. Sorafenib and dacarbazine have low single‐agent response rates in metastatic sarcomas. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of sorafenib and dacarbazine in select sarcoma s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b3deae429d6e5b6ccade4d7519f045
https://europepmc.org/articles/PMC6656505/
https://europepmc.org/articles/PMC6656505/
Autor:
D. R. D'Adamo, Charles G. Minard, Rachael Scott, Sandhya Devarajan, Gresel Martinez, Joel M. Reid, Susan M. Blaney, Eric S. Schafer, Stacey L. Berg, Rachel E. Rau, Brenda J. Weigel, Xiaowei Liu, Larisa Reyderman, Elizabeth Fox
Background Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose-limiting toxicities (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d90cf670a6c5f8e0d066ebf3bf3cb9b
https://europepmc.org/articles/PMC6019176/
https://europepmc.org/articles/PMC6019176/
Autor:
Shreyaskumar Patel, Jean-Yves Blay, Sebastian Bauer, Axel Le Cesne, Patrick Schöffski, Sun Young Rha, George D. Demetri, D. R. D'Adamo, Robert G. Maki, Antoine Italiano, Giovanni Grignani, Matthew Guo, Peter Hohenberger, Bartosz Chmielowski, Veridiana Pires de Camargo, Sant P. Chawla, Hans Gelderblom, Edwin Choy
Publikováno v:
Lancet
Lancet, Elsevier, 2016, 387 (10028), pp.1629-1637. ⟨10.1016/S0140-6736(15)01283-0⟩
Lancet, Elsevier, 2016, 387 (10028), pp.1629-1637. 〈http://linkinghub.elsevier.com/retrieve/pii/S0140673615012830〉. 〈10.1016/S0140-6736(15)01283-0〉
Lancet, 387(10028), 1629-1637
Lancet, Elsevier, 2016, 387 (10028), pp.1629-1637. ⟨10.1016/S0140-6736(15)01283-0⟩
Lancet, Elsevier, 2016, 387 (10028), pp.1629-1637. 〈http://linkinghub.elsevier.com/retrieve/pii/S0140673615012830〉. 〈10.1016/S0140-6736(15)01283-0〉
Lancet, 387(10028), 1629-1637
Summary Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41a1d0d83df5b6ad8e421e4b7b52dc32
https://hdl.handle.net/1887/112895
https://hdl.handle.net/1887/112895
Autor:
Sandra P. D'Angelo, Mrinal M. Gounder, Gary K. Schwartz, D. R. D'Adamo, Li-Xuan Qin, Mary Louise Keohan, Robert A. Lefkowitz, Robert G. Maki, Olivia R. McKennon, Catherine M. Hirst, Richard D. Carvajal, Mark A. Dickson, William D. Tap
Publikováno v:
Sarcoma, Vol 2015 (2015)
Sarcoma
Sarcoma
Gemcitabine (G) and docetaxel (D) are commonly used to treat recurrent/metastatic soft tissue sarcoma. This study tested the hypothesis that outcomes would be improved by addition of bevacizumab (B). The initial design was randomized double-blind tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::864adceb94a11b1d3792ae0236697ec9
https://doaj.org/article/cd110dda17d64e1596ed55225f2f7a45
https://doaj.org/article/cd110dda17d64e1596ed55225f2f7a45
Autor:
Sebastian Bauer, Patrick Schöffski, D. R. D'Adamo, Robert G. Maki, J.-Y. Blay, Charlotte Benson, Matthew Guo, Anders Krarup-Hansen
Publikováno v:
European Journal of Cancer. 72:S155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::452c0d03c23cb69f180346c8eba42a62
https://doi.org/10.1016/s0959-8049(17)30581-6
https://doi.org/10.1016/s0959-8049(17)30581-6